Semeraro N, Donati MB: Pathways of blood clotting initiation by cancer cells. In: Donati MB, Davidson JF, Garattini S (eds) Malignancy and the hemostatic system. Raven Press, New York, 1981, pp 65–82.
Slichter SJ, Weiden PL, O'Donnell MR, Storb R: Interruption of tumor-associated platelet consumption with platelet enzyme inhibitors. Blood 59: 1252–1258, 1982.
Rickles FR, Edwards RL, Barb C, Cronlund M: Abnormalities of blood coagulation in patients with cancer. Cancer 51: 301–307, 1983.
Edwards RL, Rickles FR, Cronlund M: Abnormalities of blood coagulation in patients with cancer: mononuclear cell tissue factor generation. J Lab Clin Med 98: 917–928, 1981.
Lyberg T, Hetland O, Prydz H: Synthesis of thromboplastin protein by a murine macrophage-like cell line. Thromb Haemostas 47: 154–156, 1982.
Tracy PB, Rohrbach MS, Mann KG: Functional prothrombinase complex assembly on isolated monocytes and lymphocytes. J Biol Chem 258: 7264–7267, 1983.
O'Meara RAQ, Jackson RD: Cytological observations on carcinoma. Ir J Med Sci 391: 327–328, 1958.
Gordon SG, Franks JJ, Lewis BJ: Comparison of the procoagulant activities in extracts of normal and malignant human tissue. J Natl Cancer Inst 62: 773–776, 1979.
Boggust WA, O'Brien DJ, O'Meara RAQ, Thornes RD: The coagulative factors of normal human and human cancer tissue. Ir J Med Sci 477: 131–144, 1963.
Gordon SG, Franks JJ, Lewis B: Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thrombosis Res 6: 127–137, 1975.
Curatolo L, Colucci M, Cambini AL, Poggi A, Morasca L, Donati MB, Semeraro N: Evidence that cells from experimental tumours can activate coagulation factor X. Br J Cancer 40: 228–233, 1979.
Hilgard P, Whur P: Factor X-activating activity from Lewis lung carcinoma. Br J Cancer 41: 642–643, 1980.
Gordon SG, Cross BA: A factor X-activating cysteine protease from malignant tissue. Clin Invest 67: 1665–1671, 1981.
Gralnick HR: Cancer cell procoagulant activity. Thromb Haemostas 42: 352, 1979.
Gralnick HR, Abrell E: Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukaemia. Br J Hematol 24: 89–99, 1973.
Khato J, Suzuki M, Sato H: Quantitative study of thromboplastin in various strains of Yoshida ascites hepatoma cells of rat. Gann 65: 289–294, 1974.
Niewiarowski S, Rao AK: Contribution of thrombogenic factors to the pathogenesis of atherosclerosis. Progress in Cardiovascular Diseases 26: 197–222, 1983.
Tuszynski GP, Walsh PN, Piperno JR, Koshy A: Association of coagulation factor V with the platelet cytoskeleton. J Biol Chem 257: 4557–4563, 1982.
Miletich JP, Jackson CM, Majerus PW: Properties of the factor Xa binding site on human platelets. J Biol Chem 253: 6908–6916, 1978.
Detwiler TC: Hypothetical model for the thrombin-platelet interaction. Ann NY Acad Sci 370: 67–71, 1981.
Pearlstein E, Ambrogio C, Gasic G, Karpatkin S: Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, Dansylarginine N-(3-ethyl-1, 5-pentanediyl)amide. Cancer Res 41: 4535–4539, 1981.
Lollar P, Owen WG: Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium: possible roles in the inactivation of thrombin by antithrombin III. J Clin Invest 66: 1222–1230, 1980.
Lollar P, MacIntosh S, Owen WG: Interaction of thrombin with the vascular endothelium in a recirculating Langendorff rabbit heart preparation. Ann NY Acad Sci 401: 234–240, 1982.
Esmon CT, Owen WG: Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci 78: 2249–2252, 1981.
Comp PC, Esmon CT: Activated protein C inhibits platelet prothrombin-converting activity. Blood 54: 1272–1281, 1979.
Dahlback B, Stenflo J: Inhibitor effect of activated protein C on activation of prothrombin by platelet-bound factor Xa. J Biochem 107: 331–335, 1980.
Gospodarowicz D, Brown KD, Birdwell Cr, Zetter BR: Control of proliferation of human vascular endothelial cells. J Cell Biol 77: 774–788, 1978.
Donati MB, Poggi A: Malignancy and haemostasis. Brit J Haemat 44: 173–182, 1980.
Hansson GK, Schwartz SM: Evidence for cell death in the vascular endothelium in vivo and in vitro. AJP 112: 278–286, 1983.
Gasic GJ, Gasic TB: Plasma membrane vesicles as mediators of interactions between tumor cells and components of the hemostatic and immune systems. In: Interaction of platelets and tumor cells. Alan R Liss, New York, 1982, pp 429–444.
Holmsen H, Kaplan KL, Dangelmaier CA: Differential energy requirements for platelet responses. Biochem J 208: 9–18, 1982.
Paschen W, Patscheke H, Worner P: Aggregation of activated platelets with Walker 256 carcinoma cells. Blut 38: 17–24, 1979.
Sloane BF: Lysosomal cathepsin B: correlation with metastatic potential. Science 212: 1151–1153, 1981.
Gasic GJ, Koch PAG, Hsk B, Gasic TB, Niewiarowski: Thrombogenic activity of mouse and human tumors: effects on platelets, coagulation, and fibrinolysis, and possible significance for metastases. Z Krebsforsch 86: 263–277, 1976.
Gasic GJ, Gasic TB, Jimenez SA: Effects of trypsin on the platelet-aggregating activity of mouse tumor cells. Thromb Res 10: 33–45, 1977.
Holme R, Oftebro R, Hovig T: In vitro interaction between cultured cells and human blood platelets. Thromb Haemost 40: 89–102, 1978.
Jamieson GA, Bastida E, Ordinas A: Mechanisms of platelet aggregation by human tumor cells. In: Jamieson GA (ed) Interaction of platelets and tumor cells. Alan R Liss, New York, 1982, pp 405–413.
Hara Y, Steiner M, Baldini MG: Characterization of the platelet-aggregating activity of tumor cells. Cancer Res 40: 1217–1222, 1980.
Pearlstein E, Cooper LB, Karpatkin S: Extraction and characterization of a platelet-aggregating material from SV40-transformed mouse 3T3 fibroblasts. J Lab Clin Med 93: 332–344, 1979.
Karpatkin S, Pearlstein E: Role of platelets in tumor cell metastases. Ann Int Med 95: 636–641, 1981.
Lerner WA, Pearlstein E, Ambrogio C, Karpatkin S: New mechanism for tumor-induced platelet aggregation. Comparison with mechanisms shared by other tumors with possible pharmacologic strategy toward prevention of metastases. Int J Cancer 31: 463–469, 1983.
Bastida E, Ordinas A, Giardina SL, Jamieson GA: Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase. Cancer Res 42: 4348–4352, 1982.
Gasic GJ, Boettiger D, Catalfamo JL, Gasic TB, Stewart GJ: Aggregation of platelets and cell membrane vesiculartion by rat cells transformed in vitro by Rous sarcoma virus. Cancer Res 38: 2950–2955, 1978.
Gasic GJ, Catalfamo JL, Gasic TB, Avdalovic N: In vitro mechanism of platelet aggregation by purified plasma membrane vesicles shed by mouse 15091A tumor cells. In: Donati MB (ed) Malignancy and the hemostatic system. Raven Press, New York, 1981, pp 27–35.
Cavanaugh PG, Sloane BF, Bajkowski A, Gasic GJ, Gasic TB, Honn KV: Involvement of a cathepsin B-like cysteine proteinase in platelet aggregation induced by tumor cells and their shed membrane vesicles. Clin Exp Metastasis 1: 297–307, 1983.
Dvorak HF, Quay SC, Orenstein NS, Dvorak AM, Hahn P, Bitzer AM: Tumor shedding and coagulation. Science 212: 923–924, 1981.
Gasic GJ, Gasic TB, Jimenez SA: Platelet aggregating material in mouse tumor cells: removal and regeneration. Lab Invest 36: 413–419, 1977.
Gasic GJ, Gasic TB, Stewart GJ: Mechanisms of platelet aggregation by murine tumor cell sheddings. In: Honn KV, Sloane BF (eds) Hemostatic mechanisms and metastasis. Martinus Nijhoff, Boston, 1984 (in press).
Kinlough-Rathbone RL, Packham MA, Reimers HJ, Cazenave JP, Mustard JF: Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23, 187. J Lab Clin Med 90: 707–719, 1977.
Feinman RD, Lubowsky J, Charo I, Zabinski MP: The lumiaggregometer: a new instrument for simultaneous messurement of secretion and aggregation by platelets. J Lab Clin Med 90: 125–129, 1977.
Warren BA: Platelet-tumor cell interactions: morphological studies. In: de Gaetano G, Garattini S (eds) Platelets: a multidisciplinary approach. Raven Press, New York, 1978, pp 427–446.
Ivarsson L: Pulmonary metastasis formation after trauma: an experimental study on the relevance of rheological disturbances of blood. Acta chirurgica scandanavia. Almqvist & Wiksell, Stockholm, Göteborg, 1976.
Milas L, Peters LJ: Conditioning of tissues for metastasis formation by radiation and cytotoxic drugs. In: Nicolson GL, Milas L (eds) Cancer invasion and metastasis: biologic and therapeutic aspects. Raven Press, New York, 1984, pp 321–336.
Van Putten LM, Kram LKJ, van Dierendenck HHC, Smink T, Fuzy M: Enhancement of drugs of metastatic lung nodule formation after intravenous tumor cell injection. Int J Cancer 15: 588–595, 1975.
De Brabander M, Aerts F, Borgers M: The influence of a glucocorticoid on the lodgement and development in the lungs of intravenously injected tumor cells. Eur J Cancer 10: 751–755, 1974.
Nicolson GL: Cancer metastasis: organ colonization and the cell-surface properties of malignant cells. Biochimica et Biophysica Acta 695: 113–176, 1982.
Warren BA: Cancer cell-endothelial reactions: the microinjury hypothesis and localized thrombosis in the formation of micrometastases. In: Donati MB, Davidson JE, Garanttini S (eds) Malignancy and the hemostasis system. Raven Press, New York, 1981, pp 5–26.
Gasic GJ, Viner ED, Budzynski AZ, Gasic GP: Inhibition of lung tumor colonization by leech salivary gland extracts from Haementeria ghilianii. Cancer Res 43: 1633–1636, 1983.
Murer EH, James HL, Budzynski AZ, Malinconico SM, Gasic GJ: Protease inhibitors in Haementeria leech species. Thrombosis and Haemostasis 51: 24–26, 1984.
Gasic GJ, Iwakawa I, Viner C, Viner ED, Milas L: Inhibition of metastasis promotion by cyclophosphamide (CY), cortisone (E) & local thorax irradiation (LTI) by leech salivary gland extract (SGE) from Haementeria officinalis. Proc Am Assoc Cancer Res 25: 58, 1984.
Maat B, Hilgard P: Anticoagulants and experimental metastases—evaluation of antimetastatic effects in different model systems. J Cancer Res Clin Oncol 101: 275–283, 1981.
Gralnick HR: Cancer cell procoagulant activity. In: Donati MB, Davidson JF, Garattini S (eds) Malignancy and the hemostatic system. Raven Press, New York, 1981, pp 57–64.
Gorelik E, Wiltrout RH, Okumura K, Habu S, Herberman RB: Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer 30: 107–112, 1982.
Colucci M, Giavazzi R, Alessandri G, Semeraro N, Mantovani A, Donati MB: Procoagulant activity of sarcoma sublines with different metastatic potential. Blood 57: 733–735, 1981.
Zacharski LR: Anticoagulation in the treatment of cancer in man. In: Donati MB, Davidson JF, Garattini S (eds) Malignancy and the hemostatic system. Raven Press, New York, 1981, pp 113–128.
Hilgard P, Maat B: Mechanism of lung tumour colony reduction caused by coumarin anticoagulation. Europ J Cancer 15: 183–187, 1979.
Stenflo J: A new vitamin K-dependent protein: purification from bovine plasma and preliminary characterization. J Biol Chem 251: 355–363, 1976.
Hilgard P: Experimental vitamin K deficiency and spontaneous metastases. Br J Cancer 35: 891–893, 1977.
Maat B: Selective macrophage inhibition abolishes warfarin-induced reduction of metastases. Br J Cancer 41: 313–316, 1981.
Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611–619, 1983.
Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S: Platelet-tumor-cell interactions in mice: the role of platelets in the spread of malignant disease. Int J Cancer 11: 704–718, 1973.
Boucek RJ, Alvarez TR: Increase in survival of subcultured fibroblasts mediated by serotonin. Nature New Biology 229: 61–62, 1971.
Marguerie GA, Plow EF: The fibrinogen-dependent pathway of platelet aggregation. Ann NY Acad Sci 408: 556–566, 1983.
Nachman RL, Weksler B, Ferris B: Characterization of human platelet vascular permeability-enhancing activity. J Clin Invest 51: 549–555, 1972.
Wood S: Pathenogenesis of metastasis formation observed in vivo in the rabbit ear chamber. AMA Archives of Pathology 66: 550–568, 1958.
Niewiarowski S: Proteins secreted by the platelet. Thrombos Haemostas 38: 924–938, 1977.
Capitianio AM, Niewiaroswki S, Tuszynski CP, Kornecki E, Rao K: The interaction platelet factor X with human platelets and its association with the platelet tritium X-100 insoluble cytoskeleton (Abstract). Blood 60 (suppl): 709, 1982.
Rucinski B, Niewiarowski S, James P, Walz DA, Budzynski AZ: Antiheparin proteins secreted by human platelets: purification, characterization, and radioimmunoassay. Blood 53: 47–62, 1979.
Ross R, Vogel A: The platelet-derived growth factor. Cell 14: 203–210, 1978.
Cowan DH, Graham J: Stimulation of human tumor colony formation by platelet lysate. J Lab Clin Med 102: 973–986, 1983.
Stiles CD: The molecular biology of platelet-derived growth factor. Cell 33: 653–655, 1983.
Turner WA, Menter DG, Honn KV, Taylor JD: Tumor cell-induced fibronectin release. (Abstract) Proc Am Assoc Cancer Res 23: 97, 1983.
McKeown-Longo PJ, Hanning R, Mosher DF: Binding and degradation of platelet thrombospondin by cultured fibroblasts. J Cell Biol 98: 22–28, 1984.
Meyer D, Baumgartner HR: Role of von Willebrand factor in platelet adhesion to the subendothelium. Br J Haematol 54: 1–9, 1983.
Fujimotu T, O'Hara S, Hawiger J: Thrombin-induced exposure and prostacyclin inhibition of the receptor for factor VIII/von Willebrand factor on human platelets. J Clin Invest 69: 1212–1222, 1982.
Ruan C, Tobolem G, McMichael AJ, Drouet L, Legrand Y, Degos L, Kieffer N, Lee H, Caen JP: Monoclonal antibody to human platelet glycoprotein I: II. Effects of human platelet function. Br J Haematol 49: 511–519, 1981.
Tuszynski GP, Niewiarowski S, Lawley J, Srivastava S: Thrombospondin as a potential fibrin receptor on platelets identified by affinity chromatography. (Abstract) Circulation 68 (suppl III): 317, 1983.
Gogstad GO, Hagen I, Korsmo R, Solum NO: Evidence for a separate location of platelet glycoprotein II and III in the alpha granule membrane. (Abstract) Thromb Haemost 46: 109, 1981.
Wasteson A, Glimelius B, Busch D, Westermark B, Heldin C-H, Norling B: Effect of a platelet endoglycosidase on cell surface associated heparan sulphate of human cultured endothelial and glial cells. Thromb Res 11: 309–321, 1977.
Nakajima M, Irimura T, di Ferrante D, di Ferrante N, Nicolson G: Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science 220: 611–612, 1983.
Seamon KB, Padgett W, Daly JW: Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci 78: 3363–3367, 1981.
Mussoni L, Poggi A, de Gaetano G, Donati MB: Effect of Ditazole, an inhibitor of platelet aggregation, on a metastasizing tumour in mice. Brit J Cancer 37: 126–129, 1978.
Jaffe BM, Santoro MG: Prostaglandins and cancer. Environ. Sci Res 29: 313–319, 1983.
Gasic G, Gasic T: Removal of sialic acid from the cell coat in tumor cells and vascular endothelium and its effects on metastasis. Proc Natl Acad Sci (USA) 48: 1172–1177, 1962.
Choi S-I, Simone JV, Journey LJ: Neuraminidase-induced thrombocytopenia in rats. Br J Haematol 22: 93–101, 1972.
Grottum KA, Jeremic M: Neuraminidase injections in rabbits: reduced platelet surface change, aggregation and thrombocytopenia. Thrombos Diathes Haemorrh 29: 461–469, 1973.
Greenburg J, Packham MA, Cazenave J-P, Reimers H-J, Mustard JF: Effects on platelet function of removal of platelet sialic acid by neuraminidase. Lab Invest 32: 476–484, 1975.
Gasic G, Gasic T, Stewart CC: Anti-metastatic effects associated with platelet reduction. Proc Natl Acad Sci (USA) 61: 46–52, 1968.
Morrison FS, Baldini MG: Antigenic relationship between blood platelets and vascular endothelium. Blood 33: 46–56, 1969.
Pearlstein E, Abrogio C, Karpatkin S: Lack of effect of PGI2 on the development of pulmonary metastases in mice following the intravenous injection of three syngeneic tumors; inhibition of metastases with anti-platelet antibody. (Abstract) Proceedings of the American Federation of Clinical Research, Washington DC, May 4–7, 1984.
Awouters F, Leysen JE, De Clerck F, van Nueten JM: General pharmacological profile of ketanserin (R41468), a selective 5-HT2 receptor antagonist. In: De Clerck F, Vanhoutte PM (eds) 5-Hydroxytryptamine in peripheral reactions. Raven Press, New York, 1982, pp 193–198.
Skolnik G, Ericsson LE, Bagge U: The effect of thrombocytopenia and anti-serotonin treatment on the lodgement of circulating tumor cells. J Cancer Res Clin Oncol 105: 30–37, 1983.
George JN, Thoi LL, McManus LM, Reimann TA: Isolation of human platelet membrane microparticles from plasma and serum. Blood 60: 834–840, 1982.
Gorelik E, Wiltrout RH, Brunda MJ, Holden HT, Herberman RB: Augmentation of metastasis formation by thyoglycollate-elicited macrophages. Int J Cancer 29: 575–581, 1982.
Gasic GJ, Gasic TB, Murphy S: Anti-metastatic effect of aspirin. Lancet 2: 713, 1972.
Wood S, Hilgard P: Aspirin and tumour metastasis. Lancet 2: 1416–1417, 1972.
Hilgard P, Schmidt CG: The influence of platelet aggregation inhibitors on metastasis formation in mice (3LL). Z Krebsforsch 86: 243–250, 1976.
Honn KV, Cicone B, Skoff A: Prostacyclin: a potent antimetastatic agent. Science 212: 1270–1272, 1981.
Menter DG, Onoda JM, Taylor JD, Honn KV: Effects of prostacyclin on tumor cell-induced platelet aggregation. Cancer Res 44: 450–456, 1984.
Kohga S, Kinjo M, Tanaka K, Ogawa H, Ishihara M, Tanaka N: Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-C]pyridine hydrocloride (ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis. Cancer Res 41: 4710–4714, 1981.
Agarwal KC, Parks RE: Forskolin: a potential antimetastatic agent. Int J Cancer 32: 801–804, 1983.
Honn KV: Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clin Expl Metastasis 1: 103–114, 1983.
Honn KV, Busse WD, Sloane BF: Prostacyclin and thromboxanes: implications for their role in tumor cell metastasis. Biochemical Pharmacology 32: 1–11, 1983.
Honn KV, Menter DG, Onoda JM, Taylor JD, Sloane BF: Role of prostacyclin as a natural deterrent to hematogenous tumor metastasis. In: Nicolson GL, Milas L (eds) Tumor invasion and metastasis. Raven Press, New York, 1984, pp 361–388.
Kolenich JJ, Mansour EG, Flynn A: Haematological effects of aspirin. Lancet 2: 714, 1972.
Atherton A, Busfield D, Hellmann K: The effects of an antimetastatic agent, (=)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane (ICRF 159), on platelet behavior. Cancer Res 35: 953–957, 1975.
Gordon S, Witul M, Cohen H, Sciandra J, Williams P, Gastpar H, Murphy GP, Ambrus JL: Studies of platelet aggregation inhibitors in vivo VIII; effect of pentoxifylline on spontaneous metastases. J Med 10: 435–441, 1979.